Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
How Trump could restore capital punishment in Washington...
Epstein estate to begin handing files to House...
Sun Summit Drills 78.0 Meters of 3.72 g/t...
Juggernaut Samples up to 256.60 g/t Or 8.25...
Kenvue stock drops 10% on report RFK Jr....
Trump delivers ultimatum to Hamas: hostages home or...
Trump delivers ultimatum to Hamas: Accept deal and...
Rand Paul rips JD Vance’s assertion that executing...
Trump’s energy price promise is coming due. He...
From ‘legislative terrorists’ to center of Trump’s DC...
How Trump could restore capital punishment in Washington...
Epstein estate to begin handing files to House...
Sun Summit Drills 78.0 Meters of 3.72 g/t...
Juggernaut Samples up to 256.60 g/t Or 8.25...
Kenvue stock drops 10% on report RFK Jr....
Trump delivers ultimatum to Hamas: hostages home or...
Trump delivers ultimatum to Hamas: Accept deal and...
Rand Paul rips JD Vance’s assertion that executing...
Trump’s energy price promise is coming due. He...
From ‘legislative terrorists’ to center of Trump’s DC...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Investing

Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option

by admin October 12, 2024
October 12, 2024
Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (‘Cardiol’ or the ‘Company’), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that, further to its successfully completed public offering of an aggregate of 8,437,500 Class A common shares of the Company (the ‘Common Shares’) at a price to the public of US$1.60 per Common Share (the ‘Offering Price’) for gross proceeds of US$13.5 million (the ‘Offering’), Canaccord Genuity has purchased an additional 1,265,625 Common Shares at the Offering Price pursuant to their exercise in full of the over-allotment option (the ‘Over-Allotment Option’), for additional gross proceeds to the Company of $2,025,000 before deducting the underwriting commissions.

After giving effect to the full exercise of the Over-Allotment Option, Cardiol sold 9,703,125 Common Shares under the Offering, for aggregate gross proceeds of US$15,525,000.

The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses.

Canaccord Genuity acted as the sole bookrunner in connection with the Offering.

The Offering was made pursuant to a U.S. registration statement on Form F-10, declared effective by the U.S. Securities and Exchange Commissions (the ‘SEC’) on July 16, 2024 (the ‘Registration Statement’), and the Company’s existing Canadian short form base shelf prospectus (the ‘Base Prospectus’) dated July 12, 2024. A preliminary prospectus supplement relating to the Offering was filed with the securities commission in all of the provinces and territories of Canada, except Quebec, and with the SEC in the United States, and a final prospectus supplement relating to the Offering (the ‘Supplement’) was filed with the securities commissions in all of the provinces and territories of Canada, except Quebec, and with the SEC in the United States. The Supplement and accompanying Base Prospectus contain important detailed information about the Offering.

The Supplement and accompanying Base Prospectus can be found on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Copies of the Supplement and accompanying Base Prospectus may also be obtained from Canaccord Genuity LLC, 1 Post Office Square, Suite 3000, Boston, Massachusetts 02109, Attn: Syndicate Department, or by email at prospectus@cgf.com.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease.

Cautionary statement regarding forward-looking information:

This news release contains ‘forward-looking information’ within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are ‘forward-looking information’. Forward looking information contained herein may include, but is not limited to statements regarding the anticipated use of proceeds from the Offering. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission and Canadian securities regulators on April 1, 2024, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read the Supplement, the accompanying Base Prospectus and the documents incorporated by reference therein.

For further information, please contact:

Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226366

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

previous post
West High YieldResources Ltd. Announces Extension of Current Private Placement
next post
DAVID MARCUS: The top 5 twists that put Trump back in command

You may also like

Altech – CERENERGY Cells Test Safe Under Extreme...

April 3, 2025

Should You Invest in Silver Bullion? (Updated 2024)

November 1, 2024

Seismic Disruptions Could Cost Copper and Rhenium Industries...

July 20, 2024

Heritage Mining Zone 3 Successful SGH Soil Survey

July 25, 2024

Opawica Explorations Commences Drill Program at its Bazooka...

February 20, 2025

Holding(s) in Company

November 16, 2024

Biden Admin Awards Intel US$7.9 Billion for Semiconductor...

November 28, 2024

Copper Prices Surpass US$10,000 as US Tariff Fears...

March 22, 2025

How to Invest in Tin Stocks (Updated 2024)

November 21, 2024

E-Power Resources Inc. Announces Flow-Through and Hard Dollar...

June 12, 2025

Altech – CERENERGY Cells Test Safe Under Extreme...

April 3, 2025

Should You Invest in Silver Bullion? (Updated 2024)

November 1, 2024

Seismic Disruptions Could Cost Copper and Rhenium Industries...

July 20, 2024

Heritage Mining Zone 3 Successful SGH Soil Survey

July 25, 2024

Opawica Explorations Commences Drill Program at its Bazooka...

February 20, 2025

Holding(s) in Company

November 16, 2024

Biden Admin Awards Intel US$7.9 Billion for Semiconductor...

November 28, 2024

Copper Prices Surpass US$10,000 as US Tariff Fears...

March 22, 2025

How to Invest in Tin Stocks (Updated 2024)

November 21, 2024

E-Power Resources Inc. Announces Flow-Through and Hard Dollar...

June 12, 2025

Recent Posts

  • Trump delivers ultimatum to Hamas: hostages home or pay the consequences
  • Trump delivers ultimatum to Hamas: Accept deal and release hostages or pay the consequences
  • Rand Paul rips JD Vance’s assertion that executing cartel members is the ‘best use of our military’
  • Trump’s energy price promise is coming due. He has the power to solve the crisis
  • From ‘legislative terrorists’ to center of Trump’s DC revolution: Where key conservative caucus is now

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (913)
    • Investing (2,914)
    • Politics (3,581)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 Sightful Invest. All Rights Reserved.